Lilly Price Prediction: Case for Double-Digit Upside
Eli Lilly faces a pivotal year as its GLP-1 franchise powers revenue growth and new oral therapies expand addressable...
Knowing what to include in your retirement portfolio at 30 can set you up for success. Learn about essential assets and strategies.
20,742 articlesEli Lilly faces a pivotal year as its GLP-1 franchise powers revenue growth and new oral therapies expand addressable...
As pay-TV declines, Comcast may lean on first-party data to power targeted streaming ads. This article breaks down ho...
Investors chasing steady monthly payouts in JEPQ face a trade-off: higher income amid lower long-run gains versus bro...
Broadcom stock rose on news of a strategic partnership update disclosed in a regulatory filing. This article breaks d...
A CFO selling a substantial stake can spark questions about a company’s short-term risk and long-term strategy. This ...
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Investors are eyeing yuanbao (yb) 2026 earnings as the company pivots toward new revenue streams. This guide breaks d...
A founder sold a meaningful chunk of stock, but does that signal trouble or a routine liquidity move? This article br...
Palantir Technologies stock popped today on an earnings-tease event, not a full report. This article explains the dri...
CoreWeave has dropped substantially from its 52-week peak, leaving investors debating whether the bounce is coming or...
A new mega-listing grabbed headlines by raising $26.5 billion, ranking just below SpaceX in U.S. market history. Read...
The horizon ahead is dotted with questions about SoFi and its next investor update. This guide lays out a practical f...